LH

Laboratory Corp Amer Hldgs
NYSE

Real-time Quotes | Nasdaq Last Sale

248.55
+2.12
+0.86%
After Hours: 248.55 0 0.00% 16:33 05/20 EDT
OPEN
247.87
PREV CLOSE
246.43
HIGH
250.00
LOW
242.83
VOLUME
814.97K
TURNOVER
0
52 WEEK HIGH
317.17
52 WEEK LOW
231.34
MARKET CAP
23.04B
P/E (TTM)
11.41
1D
5D
1M
3M
1Y
5Y
LabCorp (LH) Introduces Latest Assay for Skin Cancer Patients
LabCorp's (LH) new assay is claimed to have shown a demonstrable clinical advantage in patients suffering from melanoma.
Zacks · 2d ago
Ex-Labcorp CEO David King dishes on career, the stock market and Triangle's light-rail woes
David King, who led Labcorp from a tumultuous time to becoming a Triangle juggernaut, was honored in a lively event as life science leaders packed a ballroom to listen to an industry icon.
American City Business Journals · 3d ago
2022 Life Sciences Lifetime Achievement Award winner: David King
During his 12 years leading the company, David King transformed Labcorp from a U.S.-focused diagnostics lab to a global life sciences giant.
American City Business Journals · 3d ago
BRIEF-Labcorp Launches New Test For People With Skin Cancer
reuters.com · 4d ago
Labcorp launches new test for people with skin cancer
Laboratory Corporation of America (NYSE:LH) on Wednesday said it had launched a new test to measure lymphocyte-activation gene 3 ((LAG-3)) expression levels by immunohistochemistry in tumor tissue. LAG-3 is a
Seekingalpha · 4d ago
Labcorp Reports Launch Of New Test For People With Skin Cancer
New Assay for Patient Care and Use in Clinical Trials Could Lead to Expanded Treatment Options for Melanoma BURLINGTON, N.C.--(BUSINESS WIRE)-- Finding treatment options for skin cancer may become easier with the launch
Benzinga · 4d ago
Labcorp Launches New Test for People With Skin Cancer
BURLINGTON, N.C., May 18, 2022--Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company. The new test measures Lymphocyte-activation gene 3 (LAG-3) expression l...
Business Wire · 4d ago
BRIEF-Labcorp Receives Emergency Use Authorization For First Non-Prescription At-Home Collection Kit For Combined COVID-19
reuters.com · 4d ago
More
No Data
Learn about the latest financial forecast of LH. Analyze the recent business situations of Laboratory Corp Amer Hldgs through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

35.29%Strong Buy
52.94%Buy
11.76%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LH stock price target is 314.69 with a high estimate of 360.00 and a low estimate of 215.00.
High360.00
Average314.69
Low215.00
Current 248.55
EPS
Actual
Estimate
1.713.415.126.82
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 1.34K
Institutional Holdings: 93.99M
% Owned: 101.39%
Shares Outstanding: 92.70M
TypeInstitutionsShares
Increased
360
7.09M
New
77
416.26K
Decreased
384
8.06M
Sold Out
93
1.05M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
+1.40%
Healthcare Providers & Services
+1.60%
Key Executives
Chairman/President/Chief Executive Officer/Director
Adam Schechter
Chief Financial Officer/Executive Vice President
Glenn Eisenberg
Chief Human Resource Officer/Executive Vice President
Judith Seltz
Executive Vice President/Chief Technology Officer/Chief Information Officer
Lance Berberian
Executive Vice President/Chief Marketing Officer
Amy Summy
Executive Vice President/Chief Compliance Officer/Secretary
Sandra Van Der Vaart
Executive Vice President
Brian Caveney
Executive Vice President
Paul Kirchgraber
Executive Vice President
Mark Schroeder
Senior Vice President/Chief Accounting Officer
Peter Wilkinson
Lead Director/Independent Director
Peter Neupert
Independent Director
Kerrii Anderson
Independent Director
Jean-Luc Belingard
Independent Director
Jeffrey Davis
Independent Director
D. Gary Gilliland
Independent Director
Garheng Kong
Independent Director
Richelle Parham
Independent Director
Kathryn Wengel
Independent Director
Robert Williams
No Data
No Data
About LH
Laboratory Corporation of America Holdings is a life sciences company that provides clinical laboratory and end-to-end drug development services. The Company’s business segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Through its Dx and DD segments, the Company provides diagnostic, drug development and technology enabled solutions. The Company also supports clinical trial activity in approximately 100 countries through its industry central laboratory, preclinical, and clinical development businesses. Dx segment operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. DD segment, which operates on a global scale. The Company serves a range of customers, including doctors, hospitals, pharmaceutical companies, researchers, governmental agencies, physicians and other healthcare providers. It also helps in delivering non-clinical testing services.

Webull offers kinds of Laboratory Corp. of America Holdings stock information, including NYSE:LH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LH stock methods without spending real money on the virtual paper trading platform.